KRAS TCR-engineered T cells

KRAS TCR-engineered T cells are autologous or allogeneic T cells genetically modified to express T cell receptors (TCRs) that specifically recognize mutant KRAS neoantigens presented by major histocompatibility complex (MHC) class I molecules on the surface of cancer cells. Most commonly, these therapies target hotspot KRAS mutations (such as G12D and G12V), which are prevalent in solid tumors including pancreatic ductal adenocarcinoma, colorectal cancer, and non-small-cell lung cancer. These TCR-T therapies are designed to kill tumor cells harboring KRAS mutations by recognizing peptide-HLA complexes unique to cancer cells, while sparing normal cells lacking these mutations. Unlike chimeric antigen receptor (CAR)-T cells, TCR-engineered T cells can target intracellular mutant antigens, making them especially suited for solid tumor therapy. Co-expression of costimulatory switch receptors (e.g., PD1-41BB) can further enhance TCR-T cell function and persistence in hostile tumor microenvironments. These therapies are currently experimental and under clinical development for various KRAS-mutant cancers[1][2][3][4][5].

Other names

KRAS mutant TCR-T cellsKRAS-targeted TCR-engineered T cellsmKRAS TCR-TKRAS G12D TCR-TKRAS G12V TCR-T